First Quadrant’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

First Quadrant’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,900	Closed	-$204K	–	763
2019 Q1	$204K	Sell	16,900 -8,800	-34%	-$130K	0.02%	486
2018 Q4	$323K	Hold	25,700	–	–	0.03%	435
2018 Q3	$381K	Buy	25,700 +314	+1%	+$4.94K	0.01%	534
2018 Q2	$427K	Hold	25,386	–	–	0.01%	510
2018 Q1	$581K	Sell	25,386 -12,428	-33%	-$276K	0.01%	470
2017 Q4	$978K	Buy	+37,814	New	+$761K	0.02%	442

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Quadrant's CNCE Position: Q2 2019 in Review

First Quadrant sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 16,900 shares — an estimated $204K sold.

First Quadrant first reported a position in CNCE in Q4 2017 and held it in 6 quarters. The position peaked at $978K in Q4 2017. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

First Quadrant reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
First Quadrant sold 16,900 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $204K.
First Quadrant first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 6 quarters.
First Quadrant's Concert Pharmaceuticals, Inc. position peaked at $978K in Q4 2017.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on First Quadrant's 13F filing for Q2 2019, filed 24 Jul 2019.